Journal of Intellectual Property Law
Volume 30

Issue 1

Article 6

December 2022

Inventing the Right Drug: Artificial Intelligence May Just be the
Cure for an Antiquated Patent System
Matthew Hashemi
University of Georgia, jwt74222@uga.edu

Follow this and additional works at: https://digitalcommons.law.uga.edu/jipl

Recommended Citation
Matthew Hashemi, Inventing the Right Drug: Artificial Intelligence May Just be the Cure for an Antiquated
Patent System, 30 J. INTELL. PROP. L. 169 (2022).
Available at: https://digitalcommons.law.uga.edu/jipl/vol30/iss1/6

This Notes is brought to you for free and open access by Digital Commons @ University of Georgia School of Law.
It has been accepted for inclusion in Journal of Intellectual Property Law by an authorized editor of Digital
Commons @ University of Georgia School of Law. Please share how you have benefited from this access For more
information, please contact tstriepe@uga.edu.

Inventing the Right Drug: Artificial Intelligence May Just be the Cure for an
Antiquated Patent System
Cover Page Footnote
J.D. Candidate, 2024, University of Georgia School of Law, M.B.A. Candidate, University of Georgia, Terry
College of Business, 2024. I would like to dedicate this Note to my family. Thank you for your unwavering
support and encouragement.

This notes is available in Journal of Intellectual Property Law: https://digitalcommons.law.uga.edu/jipl/vol30/iss1/6

Hashemi: Inventing the Right Drug

INVENTING THE RIGHT DRUG: ARTIFICIAL
INTELLIGENCE MAY JUST BE THE CURE FOR AN
ANTIQUATED PATENT SYSTEM
Matthew Hashemi*

*

J.D. Candidate, 2024, University of Georgia School of Law, M.B.A. Candidate, University of
Georgia, Terry College of Business, 2024. I would like to dedicate this Note to my family.
Thank you for your unwavering support and encouragement.

169

Published by Digital Commons @ University of Georgia School of Law, 2022

1

Journal of Intellectual Property Law, Vol. 30, Iss. 1 [2022], Art. 6

170

J. INTELL. PROP. L.

[Vol. 30:2022]

TABLE OF CONTENTS
I.

INTRODUCTION ................................................................................. 171

II.

BACKGROUND ................................................................................... 172
A. NATURAL INTELLIGENCE VS. ARTIFICIAL INTELLIGENCE 172
B. HISTORY OF PATENT LAW ....................................................... 175
C. PATENT LAW TODAY ................................................................ 176

III.

ANALYSIS.... ........................................................................................ 182
A. SAVING LIVES THROUGH ARTIFICIAL INTELLIGENCE ...... 182
B. DEMAND FOR REFORM ............................................................ 183
C. RESISTANCE TO ARTIFICIAL INTELLIGENCE PATENT
PROTECTION .............................................................................. 184
D. FUTURE DEVELOPMENT: PROTECTING ARTIFICIAL
INTELLIGENCE INVENTIONS................................................... 185
1. Standard of Patentability...................................................... 186
2. Patent Exclusivity ................................................................. 186

IV.

CONCLUSION ...................................................................................... 187

https://digitalcommons.law.uga.edu/jipl/vol30/iss1/6

2

Hashemi: Inventing the Right Drug

INVENTING THE RIGHT DRUG

171

I. INTRODUCTION
Artificial Intelligence, also known as “AI,” is a revolutionary technology that
makes it possible for machines to learn from experience, adjust to new inputs,
and perform human-like tasks.1 AI has the power to reshape how society
innovates, integrates information, analyzes data, and generates solutions.2 In
particular, AI has begun to play a critical role in the pharmaceutical industry by
transforming drug discovery, manufacturing, diagnostics, and treatment.3 But
this technological revolution also comes with inherent uncertainty under the
current United States patent system, especially about the patentability of
inventions created by AI.4 Although the purpose behind United States patent law
is to encourage innovation, patent protection currently cannot be obtained for
inventions created by AI.5 Accordingly, industries such as the pharmaceutical
industry, which require incentives to innovate, cannot realize these incentives
without patent protection for inventions created by AI.6 Therefore, to satisfy the
need regarding incentives to innovate in the pharmaceutical industry, Congress
must consider reforming the scope of patent protection to sufficiently
encompass inventions created by AI.
This Note will focus on the current scope of patent protection under the U.S.
patent system and issues of patentability for the pharmaceutical industry in the
era of AI technology. The Note will first provide a background on AI technology
and its application in the pharmaceutical industry. The background section of
this Note will then discuss the brief history behind the U.S. patent law system
and its development through legislation over time. This section further details
1 Artificial Intelligence What it is and why it matters, SAS,
https://www.sas.com/en_us/insights/analytics/what-is-artificial-intelligence.html (last
visited Oct. 27, 2021).
2 Darrell M. West & John R. Allen, How artificial intelligence is transforming the world, BROOKINGS
(Apr. 24, 2018), https://www.brookings.edu/research/how-artificial-intelligence-istransforming-the-world/.
3 Samantha McGrail, AI in the Pharma Industry: Current Uses, Best Cases, Digital Future,
PHARMANEWSINTEL. (Apr. 30, 2021), https://pharmanewsintel.com/news/ai-in-thepharma-industry-current-uses-best-cases-digital-future.
4 Susan Decker, One Man’s Quest to Get an AI Machine a Patent Gathers Momentum, BLOOMBERG
L. NEWS (Aug. 8, 2021, 9:19 AM), https://www.bloomberg.com/news/articles/2021-0821/one-man-s-quest-to-get-an-ai-machine-a-patent-gathers-momentum.
5 Id.; Elif Kavusturan, Reforming U.S. Patent Law to Enable Access to Essential Medicines in the Era
of Artificial Intelligence, 18 NW. J. TECH. & INTELL. PROP. 51, 78-79 (2020); U.S. CONST. art. I, §
8.
6 Richard D. Nelson & Roberto Mazzoleni, Intellectual Property Rights and the Dissemination Of
Research Tools In Molecular Biology, NCBI 17 (1996), https://www.ncbi.nlm.nih.gov/books/
NBK233537/pdf/Bookshelf_NBK233537.pdf.

Published by Digital Commons @ University of Georgia School of Law, 2022

3

Journal of Intellectual Property Law, Vol. 30, Iss. 1 [2022], Art. 6

172

J. INTELL. PROP. L.

[Vol. 30:2022]

the current state of patent law on who may seek patent protection, which types
of intellectual property are covered by patents, and the process of obtaining
patent protection. This section concludes with a discussion of how inventions
created by AI are classified and the limited patent protection currently offered
for AI under the U.S. patent system. Section III of this Note analyzes the
beneficial impact of AI in the pharmaceutical industry and calls for patent law
reform to protect drugs invented by AI. In addition, Section III considers and
rebuts potential arguments in resistance to AI patent protection. Section III
further proposes reforms and solutions that Congress should consider to ensure
that patent law will encompass and protect drug inventions created by AI.
Finally, this Note concludes with a discussion of how expanding patent
protection for AI in the pharmaceutical industry will efficiently incentivize
innovation and promote public health.
II. BACKGROUND
A. NATURAL INTELLIGENCE VS. ARTIFICIAL INTELLIGENCE
Human beings are widely considered to hold the highest level of biological
intelligence ever observed.7 As rational beings, humans can solve various
complex issues through experience and intuition, supplemented by rules of logic,
decision analysis, and statistics.8 This sort of biological or “natural” intelligence
encompasses the ability to autonomously and efficiently accomplish complex
goals that are restricted to “things that only humans can do.”9
Natural intelligence is generated through biological neural networks of flesh
and blood, which make up the human brain.10 Unlike other forms of intelligence,
natural intelligence has given humans the ability to learn, multitask, and combat
various multifaceted situations over time.11 Due to such an immense cognitive
capacity, the human brain can solve various arithmetic, conceptual, spatial,
economic, socio-organizational, and political problems.12 Even though the
natural intelligence of humans is high compared to other animal species, “in

7 J.E.H. Korteling et al., Human- versus Artificial Intelligence, FRONTIERS A.I. (Mar. 25, 2021),
https://doi.org/10.3389/frai.2021.622364.
8 Id.
9 Id.
10 Id.
11 Shivangi Sinha & Anwesha Pathak, Artificial Intelligence Vs Natural (Human) IntelligenceGlobal Challenge for Human Rights, 14 INT’L J. APPLIED ENG’G RSCH. 18, 19 (2019),
https://www.ripublication.com/ijaerspl2019/ijaerv14n7spl_05.pdf.
12 Korteling et al., supra note 7.
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absolute terms[,] it may be very limited in its physical computing capacity.”13 On
the other hand, machine learning or AI has become the cornerstone of
innovation and has built upon natural intelligence to replicate and exceed how
humans perceive and react to the world.14
AI refers to systems or machines that mimic natural intelligence to perform
tasks and can iteratively enhance themselves based on the information and data
collected.15 AI systems generally consist of several databases, operations, and
control modules interacting in a complex fashion to form an automatic problemsolving system.16
AI systems may either be categorized as weak or strong AI.17 Weak AI is
designed to perform a single or “narrow” task and cannot solve other problems
outside of its specific field.18 Strong AI, on the contrary, is programmed to think
and reason autonomously.19 The quintessential form, or “holy grail,” of AI
technology is General AI, capable of solving issues and achieving goals just as
well as humans through comparable cognitive, emotional and social behavior.20
Although many believe AI refers to human-like robots and machines, AI
systems are not intended to replace the natural intelligence of human beings.21
Conversely, the underlying purpose behind AI technology is to “significantly
enhance human capabilities and contributions.”22 AI has significant advantages
given its ability to solve problems at significant speeds, its ability to work 24/7,
and its ability to collect information and formulate solutions without bias.23 In
particular, the development of machine learning technology has drastically
transformed the effectiveness of AI systems.24
Machine learning is an analytical process in which an AI system
autonomously derives rules and procedures from patterns within a data set and
creates explanations or predictions.25 These rules and patterns derived through
Id.
What is AI? Learn About Artificial Intelligence, ORACLE CLOUD INFRASTRUCTURE (Oct. 1,
2021), https://www.oracle.com/artificial-intelligence/what-is-ai/.
15 Id.
16 NILS J. NILSSON, PRINCIPLES OF ARTIFICIAL INTELLIGENCE (SYMBOLIC COMPUTATION) 17
(Springer-Verlag eds., 1982).
17 Kavusturan, supra note 5, at 57.
18 Id.
19 Id.
20 Id.
21 What is AI? Learn About Artificial Intelligence, supra note 14.
22 Id.
23 Sinha & Pathak, supra note 11, at 19.
24 See Kavusturan, supra note 5, at 58 (outlining the use of machine learning technology,
which has helped minimize expenses and increase efficiency).
25 Id.
13
14

Published by Digital Commons @ University of Georgia School of Law, 2022

5

Journal of Intellectual Property Law, Vol. 30, Iss. 1 [2022], Art. 6

174

J. INTELL. PROP. L.

[Vol. 30:2022]

the machine learning process are then used to formulate and test hypotheses and
solutions for an issue.26 The capabilities of machine learning technology can
significantly benefit researchers through AI technology’s ability to focus on
specific problems and offer solutions to various problems based on available
data.27
The many advantages of AI technology and machine learning allow society
to transform numerous industries, from autonomous cars to drug discovery.28 In
particular, the pharmaceutical industry has taken great interest in AI and its
potential to drastically impact the field of medicine.29 Traditionally, developing
and discovering a novel targeted drug is a costly and long-term process, costing
billions of dollars, with a development process exceeding ten years.30
Discovering new drugs is extremely complex, as “[i]t requires navigating a
combinatorial space of more than 10⁶⁰ molecules [in order] to find a suitable
drug candidate.”31 Despite such challenges, the digitization and advancement of
AI technology—especially through machine learning—has considerably
increased the potential of discovering new drugs.32
Implementing AI to aid in drug development, for instance, has allowed
specialists to find a novel antibiotic, Halicin, and various other drug candidates,
out of more than 100 million molecules, in a fraction of the time required by
traditional methods.33 In addition to antibiotics, AI has also been implemented
to accelerate the search for the COVID-19 vaccine.34 Therefore, AI technology
has been proven to identify new drug molecules or new uses for old drugs.35 The
current advancements in AI technology have unquestionably boosted target drug
discovery at an unprecedented speed, leading AI to be recognized as one of the
“must-win technologies of the future.”36

Id.
Id.
28 Decker, supra note 4.
29 See generally Augmented intelligence in health care, AM. MED. ASS’N (2018), https://www.amaassn.org/system/files/2019-01/augmented-intelligence-policy-report.pdf (discussing the
potential effects of AI in healthcare).
30 Benquan Liu et al., Artificial intelligence and big data facilitated targeted drug discovery, STROKE &
VASCULAR NEUROLOGY 206 (Nov. 7, 2019),
https://svn.bmj.com/content/svnbmj/4/4/206.full.pdf.
31 Bowen Lou & Lynn Wu, AI on Drugs: Can Artificial Intelligence Accelerate Drug Development?
Evidence from a Large-Scale Examination of Bio-Pharma Firms, MIS Q. 2 (citations omitted),
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524985 (last updated June 6, 2022).
32 Id.
33 Id.
34 Id. at 3.
35 Decker, supra note 4.
36 Id.; see also Liu et al., supra note 30, at 212 (demonstrating how the integration of artificial
26
27
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B. HISTORY OF PATENT LAW
The purpose of a patent is to offer protection to an inventor of “any new
and useful process, machine, manufacture or composition of matter.”37 Holding
a patent provides an owner of an invention with “the right to exclude others
from making, using, offering for sale, or selling” the owner’s invention in the
U.S. or importing the owner’s invention into the U.S.38
The foundation of U.S. patent law dates back to the medieval era in England,
where kings and queens would grant exclusive rights, or monopolies, called
“letters patents” over everyday goods.39 These letters patents allowed the holders
to possess exclusive control over the market for a particular good.40 The holders
of the letters patents had the power to search stores and houses of suspected
infringers and collect penalties from any person caught selling goods in
competition with the exclusive holder.41 Nevertheless, in 1642, the English
Parliament’s enactment of the Statute of Monopolies effectively restricted the
King from granting letters patents for common everyday goods.42 But the statute
allowed for monopolies over certain goods, particularly products that were new
to England.43 The Statute allowed holders to maintain their monopolies for 14
years to encourage merchants to invest in new products and inventions.44
In the late 1700s, during the drafting of the United States Constitution,
English patent law became the accepted model for encouraging invention.45
Under the accepted English model, the Framers of the Constitution vested
Congress with the power “[t]o promote the progress and Science of useful Arts,
by securing, for limited Times, to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries.”46 Authorized with this power,
Congress enacted a sequence of comprehensive patent statutes in response to
intelligence and big data has made a large impact in the discovery process of novel targeted
drugs).
37 35 U.S.C. § 101.
38 General information concerning patents, USPTO,
https://www.uspto.gov/patents/basics/general-information-patents (last visited Oct. 26,
2021).
39 Maurice M. Klee, Where Did the U.S. Patent Laws Come From?, 17 IEEE ENG’R MED. &
BIOLOGY 135 (1998), https://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=646231.
40 Id.
41 Id.
42 Id.
43 Id.
44 Id.
45 Id.
46 Id. (quoting U.S. CONST. art. I, § 8).
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the U.S.’s continued efforts and perceived need to encourage and foster
innovation.47
Before 1836, patents in the U.S. could be granted to inventors without
review or examination.48 This practice proved to be noticeably ineffective, as the
issue of patentability was left solely in the hands of the courts.49 To address this
issue, Congress established the Patent Office in 1836, vesting it with the power
to conduct thorough examinations of proposed inventions and review “prior art”
before a patent could be issued.50 Congress also authorized the Patent Office to
resolve disputes among inventors and disseminate technical information
contained in patents to the public.51
In 1836, Congress mandated that all patent applications include a claim
pinpointing exactly what the inventor considers to be their invention.52 The
examination procedures established by Congress created a “presumption of
validity” for all issued patents, entitling patent owners to damages for
infringement suits absent “any satisfactory proof to the contrary.”53 The
presumption of validity was later codified in 1952 in the Patent Statute.54 Despite
the various developments and changes to patent law over time, inventors
continue to take advantage of the patent system and undoubtedly use patent law
as a catalyst for technological innovation.55

C. PATENT LAW TODAY
There is a recognized concern that inventors will lose motivation to innovate
and invent without legal protection afforded by patent rights since any invention
would be free to copy.56 The American patent law system has long been hailed
as a key to national innovation and a crucial incentive for inventors to create new
inventions.57 Under current U.S. patent law, a patent for an invention is generally
considered to be a grant of a property right that is issued by the United States
Id.
Id.
49 Id.
50 Id.
51 Id.
52 Id.
53 Id. (citing 35 U.S.C. § 282).
54 Id.
55 Id.
56 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS (2020).
57 Id.
47
48
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Patent and Trademark Office (“USPTO”).58 An inventor who successfully
obtains patent protection is “[granted] ‘the right to exclude others from making,
using, offering for sale, or selling’ the invention in the United States or
‘importing’ the invention into the United States.”59 Patent protection, however,
does not include positive rights, but only the negative right to exclude others
from copying a patented invention.60
Patent protection spans twenty years from the date the patent application
was filed and is only applicable within the U.S. and U.S. territories.61 Patent rights
bear similar characteristics to rights in personal property and thus can be assigned
or sold to others.62 Patent rights are also commonly transferred to other parties
through contractual agreements, known as license agreements.63
Obtaining patent protection begins with filing an application with the
USPTO.64 Upon filing an application with the USPTO, a patent examiner
reviews the application to determine if the invention meets the requirements for
patentability.65 If a patent application meets all the requirements for patentability,
then a patent may be issued to the inventor.66 On the other hand, if an application
fails to meet any of the requirements, then the application must be rejected.67
When an examiner rejects a patent application, an inventor can amend their
patent application to overcome the rejection.68
To obtain patent protection, an invention must satisfy specific requirements,
including patentable subject matter, novelty, usefulness, and non-obviousness.69
General Information Concerning Patents, supra note 38.
Id. (citation omitted).
60 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 7 (2020).
61 General Information Concerning Patents, supra note 38.
62 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 7 (2020); see, e.g., Beech Aircraft Corp. v. EDO Corp., 990 F.2d 1237, 1248 (Fed.
Cir. 1993) (articulating the principle that an inventor, who is initially vested with the patent
rights of an invention, may transfer such patent rights to another, barring any restrictions to
the contrary).
63 See KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 7-8 (2020) (Licensing agreements involve a contractual agreement where a patent
owner permits another party “to make, use, import or sell” their patented invention in
exchange for payment).
64 35 U.S.C. § 111; see also id. (discussing the process of filing a patent application with the
USPTO).
65 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 9 (2020).
66 Id.
67 Id.
68 Id.
69 Patentability Requirements, JUSTIA, https://www.justia.com/intellectualproperty/patents/patentability-requirements/ (last visited Oct. 27, 2021).
58
59

Published by Digital Commons @ University of Georgia School of Law, 2022

9

Journal of Intellectual Property Law, Vol. 30, Iss. 1 [2022], Art. 6

178

J. INTELL. PROP. L.

[Vol. 30:2022]

For an invention to be considered patentable subject matter, it must fall within
one of the statutorily defined categories of subject matter under Section 101 of
the Patent Act.70 As specified under Section 101, an inventor may obtain a patent
for “any new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof.”71 But even with such a
seemingly vast scope of patentable subject matter, “the Supreme Court ‘has long
held that this provision contains an implicit exception[].’”72 That exception is
that subject matter pertaining to “[l]aws of nature, natural phenomena, and
abstract ideas are not patentable.”73
Courts will therefore apply a two-part test to determine if the subject matter
of a proposed invention falls under one of the Supreme Court’s listed
exceptions.74 Under the first prong of the test, a court will decide whether the
claimed invention is directed to one of the proscribed exceptions.75 If so, the
court must then move to the second prong of the test to discern whether the
claimed invention includes an “inventive concept.”76 An inventive concept
makes a claimed invention more than a mere patent based on a law of nature,
natural phenomenon, or an abstract idea.77 Examples of non-patentable subject
matter include “books or music, electromagnetic signals, laws of nature, and
other abstract ideas.”78 Additionally, patent protection is only granted to novel
or new inventions. A claimed invention must meet the novelty requirement
prescribed under Section 102 of the Patent Act.79 In general, “[a] person shall be
entitled to a patent unless the claimed invention was patented, described in a
printed publication, or in public use, on sale, or otherwise available to the public
before the effective filing date of the claimed invention . . . .”80 A patent,

35 U.S.C. § 101.
Id.
72 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 14 (2020) (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S.
66, 70 (2012)).
73 Mayo Collaborative Servs., 566 U.S. at 70 (quoting Diamond v. Diehr, 450 U.S. 175, 185
(1981)).
74 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 14 (2020) (citing ChargePoint, Inc. v. SemaConnect, Inc., 920 F.3d 759, 765 (Fed.
Cir. 2019)).
75 Id. (citing Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208, 217 (2014)).
76 Id.
77 Id.
78 Patentability Requirements, supra note 69.
79 35 U.S.C. § 102.
80 35 U.S.C. § 102(a)(1).
70
71
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therefore, will be rejected for lack of novelty if all features of an invention can
be found within a single earlier patent.81
A USPTO examiner will determine the lack of novelty for a claimed
invention by relying on “prior art” to establish what was known at the time of
the applicant’s claimed invention.82 For an examiner to sufficiently show a lack
of novelty, or patent “anticipation,” it must point to a single reference that
discloses all the limitations in a patent claim.83 Markedly, an exception may be
employed if a disclosure is made one year or less prior to the effective filing date
of the claimed invention.84 Although, such exceptions apply only if “the
disclosure was made by the inventor or joint inventor or by another who
obtained the subject matter disclosed . . . from the inventor or a joint inventor.”85
Ultimately, the dispositive question about the anticipation of a claimed patent
“[i]s whether one skilled in the art would reasonably understand or infer from
the [prior art reference’s] teaching that every claim element was disclosed in that
single reference.”86 The USPTO examiner, thus, has the burden of proving that
a claimed invention lacks novelty; however, it is the inventor's responsibility to
search prior patents before filing with the USPTO.87 The fundamental purpose
underlying the novelty requirement is to prevent prior art from becoming
patented again and preserve the rights of prior patent holders.88
Furthermore, to receive a patent, the subject matter of a claimed invention
must be useful.89 Although the question of beneficial or moral use has not
typically barred patent applications, logic and facts must support the claimed
utility of an invention.90 Generally, a claimed process, machine, or composition
must achieve an intended purpose in the real world to satisfy the usefulness
requirement.91 Principally, the utility of a claimed invention cannot apply to a
broad class of inventions but must instead apply specifically to the subject matter
Patentability Requirements, supra note 69.
KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 15 (2020) (citing 35 U.S.C. § 102).
83 Id. (citing Acoustic Tech., Inc. v. Itron Networked Sols., Inc., 949 F.3d 1366, 1373 (Fed.
Cir. 2020)).
84 General Information Concerning Patents, supra note 38.
85 35 U.S.C. § 102(b)(1)(A).
86 Dayco Prods., Inc. v. Total Containment, Inc., 329 F.3d 1358, 1368 (Fed. Cir. 2003)
(citations omitted).
87 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 15 (2020); Patentability Requirements, supra note 69.
88 Patentability Requirements, supra note 69.
89 Id.
90 Id.; Patent, Legal Information Institute, CORNELL L. SCH.,
https://www.law.cornell.edu/wex/patent (last visited on Oct. 27, 2021).
91 Patent, supra note 90.
81
82
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of the claimed invention.92 An alleged utility that allows a researcher to discover
further or identify the real-world use of the claimed invention is not sufficient.93
To satisfy the utility requirement, an inventor must ultimately show a specifically
defined real-world use of their invention.94
Lastly, a claimed invention must satisfy the requirement of non-obviousness
to qualify as patentable.95 Section 103 of the Patent Act outlines the nonobviousness requirement, which provides that a patent cannot be granted for
inventions that are “obvious extension[s] of the prior art.”96 The Supreme Court
has dictated four factors that must be considered in deciding whether prior art
renders a claimed invention as obvious.97 The first factor considered is the scope
and content of the prior art.98 Next, an examiner will consider any differences
between the prior art and the claimed invention.99 Third, an examiner will then
consider the level of ordinary skill of a person in the art.100 Finally, an examiner
must account for any secondary considerations of non-obviousness.101
Secondary considerations may include commercial success, long-felt but
unsolved needs, and the failure of others to create the invention, which may
provide evidence of whether the claimed invention would have been obvious at
the time of invention.102 A claimed invention will fail to meet the requirement of
non-obviousness if “someone knowledgeable about the area would look at [the
claimed] invention and consider it to be already known; not exactly but rather
known if one were to combine several references.”103
AI has become an increasingly robust tool of innovation within modern
industries.104 Some analysts suspect it will only be a short time until AI is
responsible for most inventions.105 Yet under current patent law in the U.S., only
Id.
Id.
94 Id.
95 KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 16 (2020) (citing Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966)).
96 Id. (citing 35 U.S.C. § 103).
97 Id. (citing Graham, 383 U.S. at 1, holding that the non-obviousness of a claimed invention
may be determined through four basic factual inquiries).
98 Id.
99 Id.
100 Id.
101 Id.
102 Id.
103 Gene Quinn, Patentability: The Nonobviousness Requirement of 35 U.S.C. 103, IP WATCHDOG
(June 17, 2017, 10:00 AM), https://www.ipwatchdog.com/2017/06/17/patentabilitynonobviousness-35-usc-103/id=84716/.
104 W. Michael Schuster, Artificial Intelligence and Patent Ownership, 75 WASH. & LEE L. REV.
1945, 1947 (2018).
105 Id.
92
93
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a “natural person” may be listed as the inventor or joint inventor when obtaining
patent protection.106 Given these inventorship requirements, the question has
emerged of whether AI-created machines may qualify as an inventor of a
patent.107 Congress has yet to address this looming question of whether and to
whom patent protection can be granted for AI inventions.108 Furthermore, the
USPTO has not provided any internal guidelines regarding domestic policy on
AI inventions.109 The patentability of AI-created inventions has thus become a
pressing issue for U.S. Courts.110
The U.S. District Court for the Eastern District of Virginia issued an
opinion—Thaler v. Hirshfeld—on September 2, 2021, regarding the patentability
of inventions created by AI.111 The court held that AI-created machines could
not be considered an “inventor” under current U.S. patent law.112 The court
specified that the definitions of “inventor” and “joint inventor” under the Patent
Act reference an “individual” or “individuals.”113 The court expressed that
whether AI-created machines could classify as an inventor depends on the plain
meaning of the statutory term “individual.”114 The court ultimately determined
that Congress was clearly referencing natural persons through the use of personal
pronouns when discussing the term “individual” under the Patent Act.115 Despite
the court holding that an “inventor” for a patent must be a natural person, it
expressed that “there may come a time when artificial intelligence reaches a level
of sophistication such that it might satisfy accepted meanings of inventorship . .
. and, if it does, it will be up to Congress to decide how . . . it wants to expand
the scope of patent law.”116
The U.S. Court of Appeals for the Federal Circuit affirmed the Eastern
District of Virginia’s decision in Thaler, holding that “[t]he Patent Act requires
that inventors must be natural persons . . . .”117 The Federal Circuit further
reasoned that the Patent Act unambiguously uses personal pronouns, such as
106 See KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 10 (2020) (citing Beech Aircraft Corp. v. EDO Corp., 990 F.2d 1237, 1248 (Fed.
Cir. 1993), specifying that only natural persons may be declared inventors).
107 Id.
108 Schuster, supra note 104, at 1948.
109 Id.
110 Id. (discussing Thaler v. Hirshfeld, 558 F. Supp. 3d 238 (E.D. Va. 2021), aff’d, Thaler v.
Vidal, 43 F.4th 1207 (Fed Cir. 2022)).
111 Thaler, 558 F. Supp. 3d at 238.
112 Id. at 247.
113 Id. at 246 (citing 35 U.S.C. § 100(f)-(g)).
114 Id. at 245.
115 Id. at 246 (citing 35 U.S.C. § 100(f)).
116 Id. at 249.
117 Thaler v. Vidal, 43 F.4th 1207, 1210 (Fed. Cir. 2022).
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“himself” and “herself,” to refer to an “individual” and does not include
pronouns such as “itself,” which Congress would have used if it intended to
permit non-human inventors.118
III. ANALYSIS
A. SAVING LIVES THROUGH ARTIFICIAL INTELLIGENCE
Discovering new drugs is daunting and largely considered to be the most
challenging part of drug research and development (“R&D”).119 Despite such
challenges, AI and machine learning can help address the intractable search
problem in discovering new drug candidates.120 AI excels at automating
projections and identifying hidden patterns or trends in data sets.121 AI can also
facilitate recombination, which helps accelerate the discovery of novel chemical
compounds under certain conditions.122 These capabilities allow AI to screen
compounds 100 times faster than humans using conventional approaches.123 AI
technology has become a versatile tool that can be applied ubiquitously during
the different stages of drug development.124 AI has proven beneficial in
identifying and validating drug targets, designing new drugs, repurposing drugs,
and improving R&D efficiency.125 AI is helping to counter the inefficiencies and
uncertainties that arise when applying classical drug development methods.126
Developing new drugs or drug compounds is an exceedingly complex and
expensive process.127 It is estimated that developing new drugs costs about 2.6
billion USD and takes an average of 12 years.128 As a result, reducing costs and
Id. at 1211.
Kit-Kay Mak & Mallikarjuna R. Pichika, Artificial intelligence in drug development: present status
and future prospects, 24 DRUG DISCOVERY TODAY 773, 775 (2019),
https://reader.elsevier.com/reader/sd/pii/S1359644618300916?token=D33D9690225DD4
AC9E3681459EC322F573B94D6891A148E0EE722E9191A6BE8C9D7F16717907B16040
10927E1CFE8E98&originRegion=us-east-1&originCreation=20221023154127.
120 Lou & Wu, supra note 31, at 1452.
121 Id.
122 Id.
123 Id.
124 Mak & Pichika, supra note 119, at 773.
125 Id.
126 Id. at 776.
127 Id.
128 H.C. Stephen Chan et al., Advancing Drug Discovery via Artificial Intelligence, 40 TRENDS IN
PHARMACOLOGICAL SCIS. 592 (2019),
https://reader.elsevier.com/reader/sd/pii/S016561471930135X?token=F069E912D747036
E100481B4BBD5FD76D58B7CD9181619C8C52E9B168E139D9028CCA322688581730B
C15C14556CBF18&originRegion=us-east-1&originCreation=20221010221649.
118
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speeding up R&D are currently central concerns for nearly all pharmaceutical
companies.129 Researchers have found that implementing AI can reduce the time
of the clinical research phase by 40% to 50% and reduce costs for U.S.
pharmaceutical companies by as much as $54 billion in R&D costs annually.130
AI has the potential to transform drug discovery by accelerating the R&D
timeline in an attempt to make drugs more affordable and increase the
probability of obtaining Food and Drug Administration approval.131 The
increasing application of AI in the pharmaceutical industry will reduce costs and
enable faster development of more effective drugs.132 Accordingly,
improvements in the pharmaceutical industry will help lead to better accessibility
to drug innovations for consumers and an overall healthier world.133
B. DEMAND FOR REFORM
AI has become a fundamental part of society, especially in the
pharmaceutical industry.134 In particular, AI technology has become essential in
developing new drugs, vaccines, and forecasting programs.135 Therefore,
obtaining patent protection for these non-obvious solutions is a critical step in
fostering R&D, large investments, and the commercial process of
pharmaceuticals.136 As U.S. patent law currently stands, only human inventors
are eligible for patent ownership.137 AI inventions pose challenges for the current
patent law regime, which was established in an era prior to the creation of AI
technology.138 For this reason, U.S. patent law reform is needed to make
pharmaceutical inventions created by AI patentable. Allowing AI to seek patent
protection for inventions will therefore incentivize pharmaceutical companies
and encourage investments in AI technology for drug R&D.139

Id.
Kevin Gawora, Fact of the Week: Artificial Intelligence Can Save Pharmaceutical Companies Almost
$54 Billion in R&D Costs Each Year, INFO. TECH. & INNOVATION FOUND. (Dec. 7, 2020),
https://itif.org/publications/2020/12/07/fact-week-artificial-intelligence-can-savepharmaceutical-companies-almost/.
131 McGrail, supra note 3.
132 Gawora, supra note 130.
133 Id.
134 Decker, supra note 4.
135 Shlomit Yanisky-Ravid & Regina Jin, Summoning a New Artificial Intelligence Patent Model: In
the Age Of Crisis, 2021 MICH. ST. L. REV. 811, 814 (2021).
136 Id. at 816.
137 Id.
138 Id. at 818.
139 Id. at 821.
129
130
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C. RESISTANCE TO ARTIFICIAL INTELLIGENCE PATENT PROTECTION
Despite the growing application of AI technology, there is still resistance
against allowing AI to obtain patents for inventions, given the view that AI does
not fit within the purposes of U.S. patent law.140 The first common point of
resistance against expanding the patent system to encompass AI is the argument
that AI patents may prevent latecomers from using or improving upon such
patented inventions.141 Despite the concern of exclusivity through patent
protection, “the patent right is not equal to the monopoly in an antitrust
sense.”142 The demand for incentives to promote new drug inventions through
patent protection is essential in some instances, such as during a health crisis
when no other efficient alternatives are available.143 Moreover, patenting AI
inventions will not necessarily prevent pharmaceutical companies from licensing
out the rights to inventions created by AI to other pharmaceutical manufacturers
and researchers.144 The licensing of AI patents can effectively accommodate
public interests—depending on the urgency and necessity of the invention’s
purported use—to ensure public access to life-saving pharmaceuticals.145
Another common point of resistance against patent law expansion is the
question of whether patents actually incentivize innovation in today’s society.146
Executives within the pharmaceutical industry have reported that 60% of new
pharmaceuticals would not have been developed without patent protection.147
The balancing of access and incentivization is essential in the pharmaceutical
industry.148 Therefore, pharmaceutical companies need patent incentives to
induce R&D activities, especially with the growing application of AI
technology.149
Another common sentiment in resistance to the expansion of patent law is
the fear that encouraging patent protection of pharmaceuticals invented by AI
will, in turn, boost price gouging and hinder further innovation by latecomers.150

140 See Thaler v. Hirshfeld, 558 F. Supp. 3d 238, 249 (“[P]laintiff’s policy arguments do not
override the overwhelming evidence that Congress intended to limit the definition of
‘inventor’ to natural persons.”).
141 Yanisky-Ravid & Jin, supra note 135, at 854-55.
142 Id. at 855.
143 Id.
144 Id.
145 Id.
146 Id. at 857.
147 Nelson & Mazzoleni, supra note 6, at 20.
148 Kavusturan, supra note 5, at 79.
149 Yanisky-Ravid & Jin, supra note 135, at 857.
150 Id. at 859.

https://digitalcommons.law.uga.edu/jipl/vol30/iss1/6

16

Hashemi: Inventing the Right Drug

INVENTING THE RIGHT DRUG

185

On the contrary, the prohibition of AI patentability would hinder innovation and
drug R&D, as it would prevent pharmaceutical companies from earning
sufficient profits and recouping decade-long R&D costs through patent
protection.151 In addition, prohibiting patent protection for inventions created
by AI would divest pharmaceutical companies of necessary incentives to
innovate with such pivotal technology.152 Conversely, some argue that other
types of intellectual property rights, such as trade secrets, are better alternatives
within AI.153 Patent protection, however, remains the most exclusive, definite,
and encompassing form of intellectual property protection.154 Trade secrets do
not present incentives to innovate, nor do they induce the dissemination of
information, as patent disclosure offers through licensing or upon patent
expiration.155 Therefore, patent protection is the best method for incentivizing
innovation while allowing public access to patented information.156
D. FUTURE DEVELOPMENT: PROTECTING ARTIFICIAL INTELLIGENCE
INVENTIONS
The goal of patent law is to provide incentives for innovation and benefits
for the public.157 Nevertheless, the current uncertainty and lack of
comprehensive policies regarding patentability in the era of AI have made the
reform of U.S. patent law inevitable.158 That being said, Congress must adhere
to the U.S. Constitution in deciding patent protection.159 Furthermore, any
patent law reform must comply with the Agreement on the Trade-Related
Aspects of Intellectual Property Rights (“TRIPS”).160 Congress, however,
remains free to amend the scope and breadth of patent rights.161 Congress can,
for example, impose conditions on patent rights, limit duration, refuse to grant
Id.
Id.
153 Id. at 857.
154 Id.
155 Id. at 858.
156 Id.
157 Kavusturan, supra note 5, at 78.
158 Decker, supra note 4, at 5.
159 Kavusturan, supra note 5, at 81.
160 Id.; see also Overview: the TRIPS Agreement, WORLD TRADE ORG.,
https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm#patents (last visited Oct. 16,
2022) (illustrating how “[t]he TRIPS Agreement requires Member countries to make patents
available for any inventions, whether products or processes, in all fields of technology
without discrimination, subject to the normal tests of novelty, inventiveness and industrial
applicability”).
161 Kavusturan, supra note 5, at 81.
151
152
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privileges or only grant rights for specific industries.162 There are several
proposals, described in the following sections, that Congress may consider
regarding the standard of patentability and patent exclusivity in the context of AI
technology.
1. Standard of Patentability
Given the current standards of U.S. patent law, only “natural persons” may
be listed as the inventor or joint inventor when seeking or obtaining patent
protection.163 Congress should consider redefining the inventorship standard to
sufficiently allow AI to be encompassed under U.S. patent law. Under the
proposed reform, U.S. patent law would be expanded to include any inventor or
joint inventor who is a natural person or AI system with the capacity to make
decisions and mimic natural intelligence autonomously. If Congress deems the
proposed patent inventorship requirement to be excessively broad, it may limit
the inventorship standard to encompass only AI systems in the pharmaceutical
industry. Redefining the inventorship standard will incentivize pharmaceutical
companies to innovate and promote access to life-saving pharmaceuticals.164
2. Patent Exclusivity
Under U.S. patent law, an inventor may enjoy the exclusivity of patent
protection for 20 years.165 If patent law is reformed to extend patent protection
to AI, Congress may express concerns about price gouging and stifling
innovation of latecomers who may attempt to develop similar drugs.166 Given
the concerns of price gouging and hindered innovation, the exclusivity period
for drugs invented by AI could be limited to 10 to 12 years. While a shortened
exclusivity period will allow for quicker information dissemination of life-saving
drugs, the proposed patent lifetime is long enough to allow pharmaceutical
companies to recoup their decade-long R&D costs.167
Furthermore, under the proposed reforms, Congress will be provided with
the option to implement compulsory licensing for essential, life-saving drugs
invented by AI. Compulsory licensing occurs when the government licenses the
rights of a patent to other companies or individuals without the patent owner’s

Id.
KEVIN T. RICHARDS, CONG. RSCH. SERV., R46525, PATENT LAW: A HANDBOOK FOR
CONGRESS 10 (2020).
164 Yanisky-Ravid & Jin, supra note 135, at 859.
165 General Information Concerning Patents, supra, note 38.
166 Yanisky-Ravid & Jin, supra note 135, at 859.
167 Id.
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permission.168 Although the U.S. patent system has generally taken a hostile
approach to compulsory licensing, pharmaceutical-specific price regulations have
been previously contemplated.169 Thus, compulsory licensing of essential
medicines patented by AI may assist with public access to essential drugs and
mitigate risks of inflated prices and price gouging.170
IV.

CONCLUSION

AI technology can significantly enhance the capability of human beings, and
countless industries have begun to implement AI to help advance innovation.171
The pharmaceutical industry, in particular, has taken a significant interest in AI
because of its potential to drastically improve the field of medicine through
R&D, large investments, and the commercial process.172 This increased
application of AI, however, comes with the issue of whether inventions created
by AI may obtain patent protection under the U.S. patent system.173 Congress
has not yet addressed this issue, and the USPTO has no internal guidelines
regarding domestic policy on AI inventions.174 The U.S. District Court for the
Easter District of Virginia and the U.S. Court of Appeals of the Federal Circuit
are the only U.S. Courts to address the issue of AI patentability in the recent
ruling of Thaler v. Hirshfeld.175 While both the Eastern District of Virginia and the
Federal Circuit ultimately held that AI-created machines could not be considered
an “inventor” under U.S. patent law, these holdings seemingly leave the door
open for Congress to decide how it wants to amend or expand the scope of
patent protection in the era of AI.176
Reforming the scope of the patent system will give Congress the authority
it needs to properly incentivize the innovation and development of novel drugs

168 William A. Reinsch, Compulsory Licensing: A Cure for Distributing the Cure?, CTR. FOR
STRATEGIC & INT’L. STUD. (May 8, 2020), https://www.csis.org/analysis/compulsorylicensing-cure-distributing-cure.
169 Justin Culbertson & Jason J. Jardine, Compulsory patent licensing in the era of pandemic, INT’L
BAR ASS’N, https://www.ibanet.org/article/36A60309-5A33-4891-8624-86A6D89A251E
(last visited Nov. 26, 2021).
170 Reinsch, supra note 168.
171 What is AI? Learn About Artificial Intelligence, supra note 14.
172 Augmented intelligence in health care, supra note 29; Yanisky-Ravid & Jin, supra note 135, at
811.
173 Schuster, supra note 104, at 1948.
174 Id.
175 Thaler v. Hirshfeld, 558 F. Supp. 3d 238 (E.D. Va. 2021), aff’d, Thaler v. Vidal, 43 F.4th
1207 (Fed Cir. 2022) (holding that AI-created machines cannot be an “inventor” under
current U.S. patent law).
176 Id. at 238, 43 F.4th at 1207.
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and medicines. The demand for incentives to innovate in the pharmaceutical
industry is evident, and Congress must address this demand by expanding patent
protection to sufficiently encompass AI technology.
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